- Home
- AMPH vs SABR Comparison
AMPH vs SABR Comparison
Compare AMPH & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPH
- SABR
- Stock Information
- Founded
- AMPH 1996
- SABR 2006
- Country
- AMPH United States
- SABR United States
- Employees
- AMPH N/A
- SABR N/A
- Industry
- AMPH Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- AMPH Health Care
- SABR Technology
- Exchange
- AMPH Nasdaq
- SABR Nasdaq
- Market Cap
- AMPH 1.3B
- SABR 1.3B
- IPO Year
- AMPH 2014
- SABR 2014
- Fundamental
- Price
- AMPH $28.29
- SABR $2.60
- Analyst Decision
- AMPH Hold
- SABR Hold
- Analyst Count
- AMPH 3
- SABR 3
- Target Price
- AMPH $43.50
- SABR $4.37
- AVG Volume (30 Days)
- AMPH 569.1K
- SABR 5.6M
- Earning Date
- AMPH 05-07-2025
- SABR 05-01-2025
- Dividend Yield
- AMPH N/A
- SABR N/A
- EPS Growth
- AMPH 17.69
- SABR N/A
- EPS
- AMPH 3.06
- SABR N/A
- Revenue
- AMPH $731,967,000.00
- SABR $3,029,565,000.00
- Revenue This Year
- AMPH $2.60
- SABR $9.82
- Revenue Next Year
- AMPH $9.42
- SABR $5.47
- P/E Ratio
- AMPH $9.25
- SABR N/A
- Revenue Growth
- AMPH 13.59
- SABR 4.19
- 52 Week Low
- AMPH $25.89
- SABR $2.29
- 52 Week High
- AMPH $53.96
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- AMPH 43.50
- SABR 25.75
- Support Level
- AMPH $28.01
- SABR $3.32
- Resistance Level
- AMPH $29.18
- SABR $3.59
- Average True Range (ATR)
- AMPH 0.79
- SABR 0.19
- MACD
- AMPH 0.35
- SABR -0.09
- Stochastic Oscillator
- AMPH 72.95
- SABR 4.63
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2023 revenue, split between distribution (78% of segment sales) and airline IT solutions (22%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.